S ex and age differences in stroke incidence suggest that female gonadal hormones provide neuroprotection for premenopausal women. 1 Although clinical use of hormone replacement therapy (HRT) for stroke remains controversial, estrogen is clearly neuroprotective in experimental models of cerebral ischemia. [1] [2] [3] [4] [5] For example, after middle cerebral artery occlusion, intact female rats sustain a smaller infarct volume than ovariectomized females or males, and this is associated with greater cerebral blood flow during ischemia. 2 Administration of estrogen to ovariectomized female rats immediately after middle cerebral artery occlusion also decreases infarct volume and increases cerebral blood flow after 1 to 2 days. 3 While a number of mechanisms likely contribute to neuroprotection, one important action appears to be the ability of estrogen to increase the vasodilatory capacity of the cerebral vasculature during cerebral ischemia. 4, 5 Recent evidence suggests that estrogen acts, in part, by increasing nitric oxide (NO) in the cerebrovascular endothelium. 6 -9 NO is produced by the enzyme endothelial nitric oxide synthase (eNOS) to cause vasodilation and inhibit platelet aggregation, both of which may be important in protection against stroke. Indeed, the effects of experimental stroke are worsened by pharmacological eNOS inhibition 10 or genetic eNOS knockout, 11 suggesting that eNOS is important for protection against brain injury. We have previously demonstrated that chronic, in vivo estrogen treatment of gonadectomized male and female rats increases levels of cerebrovascular eNOS protein 6 with a parallel increase in NOS-mediated modulation of cerebrovascular contractility. 7, 8 However, cerebrovascular NOS activity after estrogen treatment has not been measured. Therefore, we investigated the hypothesis that in vivo treatment with estrogen increases NOS activity in cerebral blood vessels.
Mechanisms underlying in vivo effects of estrogen on cerebrovascular eNOS are not known. Estrogen could act indirectly by altering one of a number of physiological factors known to influence eNOS, such as blood flow 12 or plasma lipids. 13 Conversely, endothelial cells in culture exhibit increased eNOS mRNA and protein expression in direct response to estrogen. 14 Therefore, we investigated the hypothesis that estrogen acts directly on receptors in cerebral blood vessels to increase eNOS protein. Isolated vessels were incubated in vitro with estrogen and several estrogen receptor antagonists.
Possible clinical application of these findings to human therapy may be limited, in part, by the fact that, in women with an intact uterus, estrogen is usually prescribed in combination with a progestin to decrease risk of endometrial carcinoma. One of the most commonly used progestins, medroxyprogesterone acetate (MPA), may have adverse effects on vascular protective effects of estrogen. 15 Despite the clinical relevance, there are few animal studies on effects of MPA on vascular function. In monkeys, MPA was found to negate the protective effects of estrogen against coronary artery hyperreactivity. 16 MPA also attenuated the beneficial effects of estrogen on coronary atherosclerosis in monkeys, 17 but progesterone did not. 18 In ovariectomized rats, however, progesterone was found to increase levels of subcortical infarction after middle cerebral artery occlusion. 19 To model postmenopausal HRT, we chronically administered hormones via subcutaneous silicone elastomer (Silastic, Dow Corning) capsules. Ovariectomized female rats were compared with ovariectomized females treated with estrogen alone, both estrogen and progesterone, or estrogen together with MPA. Serum hormone levels were measured, and capsule sizes were selected to give serum levels within the clinically relevant range. This model was then used to investigate whether estrogen-induced increases in eNOS would be blocked by concurrent treatment with MPA or progesterone in ovariectomized female rats.
Materials and Methods

Hormone Treatment In Vivo
All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of California at Irvine. Ovariectomized female rats received 1 of 4 possible hormone treatments: no treatment (control), estrogen, estrogen and progesterone, or estrogen and MPA. Three-month-old female Fischer 344 rats (Harlan Sprague-Dawley) were gonadectomized while anesthetized with ketamine 21.1 mg/kg and xylazine 4.2 mg/kg IP. Hormone treatment was started at the time of gonadectomy with the use of hormone-filled Silastic tubing (1.57 mm inner diameterϫ3.18 mm outer diameter) implanted subcutaneously. 17␤-Estradiol-filled tubing was 10 mm in length, as described previously. 6, 7 Progesteronefilled tubing was 90 mm in length, which was previously determined to produce physiological serum concentrations of progesterone. Tubing lengths from 1 to 150 mm were used for administration of MPA. The hormone-filled tubing remained in place until the animal was euthanatized.
After 4 weeks, animals were anesthetized with CO 2 , and blood was collected by heart puncture. Animals were decapitated, and brains were removed and either placed on ice (NOS activity assay) or frozen at Ϫ20°C (Western blot). Double-antibody 125 I-labeled radioimmunoassay kits were used to determine serum levels of 17␤-estradiol (Diagnostic Products) and progesterone (ICN Biochemicals). Serum levels of MPA were determined by first excluding endogenous steroid hormones and MPA metabolites by organic solvent and Celite column partition chromatography followed by quantification by radioimmunoassay. 20 
Vessel Isolation
Cerebral blood vessels were isolated from rat brain. 6 Three brains were pooled, gently homogenized (Dounce) in PBS (0.01 mol/L, pH 7.4), and centrifuged at 300g for 10 minutes. Pellets were resuspended in PBS, and the vessels were separated from brain parenchyma by centrifugation through 15% dextran (MW 38 400) at 1300g for 20 minutes. Pelleted blood vessels were collected on top of a nylon mesh screen (50 m) and washed extensively with a strong stream of cold PBS. Isolated vessels were kept on ice (NOS activity assay) or stored at Ϫ20°C (Western blot).
Unless noted otherwise, cerebral vessel fractions were isolated from pia-intact brains and therefore consisted of both pial and intraparenchymal blood vessels. In some cases, the pia was first removed so that only intraparenchymal cerebral blood vessels were isolated. The vessel fractions, as verified by light microscopy, contained a mixture of arteries, veins, arterioles, venules, and capillaries.
NOS Activity Assay
NOS activity was measured according to the method of Bredt and Snyder. 21 Minced cerebral vessels were aliquoted in equal amounts into assay tubes with reaction buffer ( 
In Vitro Hormone Treatment
Intact cerebral vessels from ovariectomized female rats were aliquoted into mini petri dishes containing 1.5 mL Dulbecco's modified Eagle's medium (without phenol red or sodium pyruvate) plus penicillin (10 IU/mL) and streptomycin (10 g/mL). Intact vessels were maintained at 37°C in 95% O 2 /5% CO 2 for 18 hours with drug(s) as indicated: cyclodextrin-encapsulated 17␤-estradiol, ICI 182 780, tamoxifen, cyclodextrin-progesterone, or MPA. Stock solutions (0.1 mmol/L) of ICI 182 780 and tamoxifen were prepared in 95% ethanol and diluted so that the final concentration of ethanol in the medium was approximately 0.001%. Vehicle controls contained either ethanol or 2-hydroxypropyl-␤-cyclodextrin.
Western Blot
Cerebral vessels were homogenized in 50 mmol/L ␤-glycerophosphate, 100 mol/L sodium orthovanadate, 2 mmol/L magnesium chloride, 1 mmol/L EGTA, 0.5% Triton X-100, 1 mmol/L DL-dithiothreitol, 20 mol/L pepstatin, 20 mol/L leupeptin, 0.1 U/mL aprotinin, and 1 mmol/L phenylmethylsulfonyl fluoride and then incubated on ice for 20 minutes. Samples were centrifuged at 180g for 25 minutes at 4°C, and the supernatant was collected. After protein determination (modified Lowry assay), samples were diluted in Tris-glycine SDS Sample Buffer (Novex), boiled for 4 minutes, and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)/Western blot.
For each vessel preparation, 15 g of protein was loaded in duplicate onto 8% Tris-glycine gels and separated by SDS-PAGE.
The positive control for eNOS (endothelial cells provided by Transduction Laboratories) and biotinylated broad-range molecular weight markers (Bio-Rad) also were loaded. After separation, proteins were transferred to a nitrocellulose membrane by electroblotting, and membranes were incubated overnight at 4°C in blocking buffer. Incubation with a monoclonal mouse anti-eNOS antibody (Transduction Laboratories) or mouse anti-␣ -smooth muscle actin antibody (Sigma) was followed by incubation with anti-mouse IgG antibody conjugated to horseradish peroxidase (Transduction Laboratories). Positive bands were detected by electrochemiluminescence reagent and Hyperfilm (Amersham) and quantified with a computerbased image analysis system (MCID).
To compare in vivo treatments, 1 vessel preparation from each hormonal group was run together on a single gel. Experiments were repeated a number of times (n), with preparations from different sets of animals. For each in vitro experiment, vessels were isolated and treated, and conditions were analyzed in parallel.
Data Analysis and Statistics
Data are expressed as meanϮSE. Statistical significances of Western blot and radioimmunoassay data were determined by ANOVA with Prism software, with the use of repeated measures for Western blots. Post hoc analysis was done with the Bonferroni multiple comparison test. For NOS activity studies, measurements were made in triplicate in each of 4 separate experiments, and data were analyzed by Student's t test. The acceptable level of significance was defined as PϽ0.05.
Results
In vivo estrogen treatment of ovariectomized females for 1 month significantly increased serum levels of 17␤-estradiol (Table 1) . Additional treatment with progesterone implants increased serum progesterone levels without affecting levels of 17␤-estradiol. To develop a model for MPA treatment, rats were subcutaneously implanted for 1 month with various lengths of Silastic tubing (2 to 120 mm) packed with MPA. Serum MPA levels increased in proportion with tubing length ( Table 2 ). The 3-mm length achieved serum levels (1 ng/mL) similar to those found in humans treated therapeutically with MPA (0.8 to 1.6 ng/mL), 20 and this size was used in subsequent studies of MPA. MPA treatment had no significant effect on serum levels of either 17␤-estradiol or progesterone ( Table 1) .
As expected, in vivo estrogen treatment of ovariectomized females increased uterine weight and decreased body weight compared with ovariectomized females (Table 1) . Concurrent treatment with either MPA or progesterone significantly attenuated the effects of estrogen on uterine weight and body weight.
Cerebral blood vessels isolated from the 4 hormonal treatment groups were analyzed for eNOS protein (Figure 1) . In all vessel preparations, immunoreactivity for eNOS was detected as a 140-kDa band. Only 1 band per lane was observed with anti-eNOS antibody, and this corresponded to that of the positive control. Chronic in vivo estrogen treatment of ovariectomized females resulted in a 12-fold increase in eNOS protein in cerebral vessels compared with ovariectomized females (Figure 1 ). In contrast, estrogen treatment did not affect levels of ␣-smooth muscle actin (data not shown). Concurrent in vivo treatment with estrogen and either progesterone or MPA also increased cerebrovascular eNOS, and these effects were not significantly different from those seen with estrogen alone.
Specific NOS activity, ie, activity sensitive to inhibition by L-NAME and L-NA, was measured in freshly isolated cerebral vessels. NOS activity was greater in vessels from ovariectomized females treated in vivo with estrogen compared with vessels from ovariectomized females (PϽ0.05; Figure 2 ). Similar results, ie, increased NOS activity after estrogen treatment, were obtained when intraparenchymal vessels were isolated from brains in which the pial vessels had been removed (data not shown).
For in vitro experiments with isolated cerebral vessels, cyclodextrin was used as vehicle for 17␤-estradiol and progesterone. Although cyclodextrin in millimolar concentrations can affect caveolae and eNOS, 22 preliminary experiments indicated that none of the concentrations of cyclodextrin used in the present study (10 Ϫ12 to 10 Ϫ7 mol/L) had any 
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effect on eNOS protein levels. Therefore, only the highest concentration of cyclodextrin vehicle used (10 Ϫ8 to 10 Ϫ7 mol/L) was assayed as the control. In vitro incubation with 17␤-estradiol (0.3 to 10 nmol/L) for 90 minutes had no effect on eNOS protein levels in cerebral blood vessels isolated from ovariectomized females (data not shown). Treatment for 18 hours in vitro, however, resulted in significant, concentration-dependent increases in eNOS protein compared with vehicle (PϽ0.001; Figure 3 ). As indicated in Figure 3 , the concentrations of 17␤-estradiol that increased eNOS protein levels in vitro correlated with serum levels measured in animals treated in vivo with estrogen. In contrast, the concentration of 17␤-estradiol found in sera of ovariectomized rats had no significant effect on eNOS protein levels in vitro. In cerebral vessels isolated from ovariectomized females, in vitro coincubation for 18 hours with 17␤-estradiol (1 nmol/L) and either the estrogen receptor partial agonist tamoxifen (10 nmol/L) or the antagonist ICI 182 780 (1 nmol/L) completely prevented estrogen-induced increases in eNOS protein (PϽ0.01; Figure 4A and 4B). The vehicle for the estrogen receptor antagonists (ethanol) had no significant effect on eNOS protein levels (data not shown).
Coincubation of MPA with 17␤-estradiol in vitro did not prevent the estrogen-induced increase in eNOS (5.0-fold increase in eNOS protein with 17␤-estradiol alone compared with 5.4-, 5.0-, and 5.9-fold increases after coincubation with 1, 10, and 100 ng/mL MPA, respectively; Figure 5A ). Similarly, in vitro coincubation of 17␤-estradiol with progesterone did not prevent the estrogen-induced increase in eNOS (5.2-, 5.4-, and 5.6-fold increases after coincubation with 1, 10, and 100 nmol/L progesterone, respectively; Figure 5B ).
Discussion
With the use of in vivo and in vitro rat models of HRT, this study demonstrates several important effects of estrogen on cerebral blood vessels. First, in vivo treatment of ovariectomized females with estrogen increases levels of both eNOS protein and NOS activity in cerebral blood vessels. Second, in vitro treatment of the vessels with estrogen also increases levels of eNOS protein, demonstrating that estrogen acts directly on cerebrovascular tissue. Concentrations of estrogen effective in vitro correlate with serum concentrations of estrogen that effectively increase eNOS protein in vivo, validating the relevance of the in vitro results. Third, the effect of estrogen to increase eNOS protein in vitro is completely inhibited by estrogen receptor antagonists, indicating that this action of estrogen is receptor mediated. Finally, effects of estrogen on eNOS protein are not affected by concomitant in vivo or in vitro treatment with either progesterone or MPA. These findings suggest that the various forms of HRT should all provide potentially beneficial enhancement of cerebrovascular eNOS. Serum concentrations of estrogen after in vivo treatment of ovariectomized rats correlate with levels of estrogen seen physiologically in rats 7 and measured in premenopausal females 23 and in postmenopausal women taking estrogen replacement therapy. 24, 25 The effectiveness of the in vivo estrogen treatment was confirmed by measurement of the expected increase in uterine weight.
In vivo estrogen treatment of ovariectomized rats increased levels of cerebrovascular eNOS protein, as we 6 and others 9 have shown previously. In the present study, we also found a parallel increase in NOS activity in cerebral vessels isolated from estrogen-treated animals. Intraparenchymal vessels contain only eNOS, but pial arteries can also contain perivascular neuronal NOS (nNOS)-positive nerves 26 ; therefore, we confirmed our NOS activity results using vessels isolated from brains in which the pial vessels had been removed. Furthermore, preliminary studies in our laboratory indicate that estrogen has no effect on nNOS protein (K.J. Pak, BS, et al, unpublished data, 2002). Thus, the increase in vascular NOS activity after estrogen treatment is likely due to eNOS, which is consistent with the hypothesis that estrogen increases cerebrovascular eNOS protein, resulting in increased NOS activity. These findings correlate with previous studies showing that estrogen treatment modulates vascular contractility of rat cerebral arteries by increasing NOS-dependent vasodilation. 7, 8 In vitro treatment of isolated cerebral vessels with physiological concentrations of 17␤-estradiol also increased eNOS protein. These data indicate that estrogen acts directly on the cerebrovasculature to influence NO production. Estrogen is likely acting via vascular estrogen receptors, because low concentrations of the estrogen receptor antagonist ICI 182 780 27 or the partial agonist tamoxifen 28 completely prevented estrogen-induced increases in eNOS protein in vitro. These antagonists, however, do not distinguish between estrogen receptor-␣ (ER␣) and estrogen receptor-␤ (ER␤) subtypes. Messenger RNA for both subtypes has been observed in rat aorta. 29 Our preliminary data indicate that ER␣ protein is present in rat cerebral vessels (C. Stirone, BS, et al, unpublished data, 2002), and experiments using ER␣-knockout (ERKO) mice indicate that ER␣ is necessary for in vivo effects of estrogen on cerebrovascular eNOS function and protein levels. 30 Although not specifically addressed in this study, it is likely that estrogen affects transcription of eNOS in cerebral vessels. Increases in eNOS protein were evident after 18 hours but not 90 minutes of estrogen treatment in vitro, consistent with a genomic effect. Estrogen increases eNOS mRNA in cultured endothelial cells. 14 Similarly, 18-hour in vitro incubation with estrogen increases NO release in gracilis muscle arterioles of hypertensive rats. 31 This effect appears dependent on transcription and estrogen receptor activation; however, eNOS protein or mRNA was not measured in the latter study.
Women taking HRT are often given a combination of estrogen and a progestin such as MPA. 15, 32 Of concern is the possibility that MPA may negate some of the "vascular protective" effects of estrogen. 15, 32 Few studies have used animal models to examine interactions between estrogen and MPA; however, several reports suggest detrimental effects of MPA. In monkeys, MPA, at clinically relevant serum levels, blocked the effect of estrogen to decrease vascular smooth muscle hyperreactivity. 33 MPA also prevented estrogeninduced reduction in coronary atherosclerosis in monkeys. 17 In rats, estrogen-mediated inhibition of neointima formation in the carotid artery after balloon injury was attenuated by MPA, although serum levels were not measured. 34 In our study, serum concentrations of 17␤-estradiol, progesterone, and MPA achieved by in vivo treatment correlate with human serum levels, both physiological (for progesterone, 1 to 25 ng/mL) 35 and therapeutic (for estrogen, 15 to 250 pg/mL 24, 25 ; for MPA, 0.8 to 1.6 ng/mL 20 ). This treatment with progesterone and MPA effectively prevented estrogeninduced increases in uterine weight, which in normal female rats averages 0.40Ϯ0.04 g. 6 In contrast, clinically relevant doses of progesterone and MPA had no effect on the ability of estrogen to increase eNOS levels in cerebral vessels. Similarly, in vitro exposure to progesterone and MPA did not alter estrogen-induced increases in eNOS at concentrations corresponding to in vivo serum levels (1 nmol/L and 1 ng/mL, respectively). Higher concentrations of progesterone and MPA were also without effect. Therefore, estrogenmediated increases in eNOS protein in the cerebral vasculature appear unaffected by concurrent administration of either progesterone or MPA.
Our findings are in agreement with those of several human studies showing that estrogen alone, or in combination with MPA, improves vascular function. For example, transdermal estrogen reduces internal carotid and middle cerebral artery pulsatility indexes in postmenopausal females, and MPA supplementation does not modify this effect. 36 Postmenopausal women receiving estrogen alone or with MPA show improved ischemic vasodilator responses measured by brachial artery reactivity 25 and increased plasma levels of total oxidized products of NO. 37 Therefore, in humans, estrogen in combination with MPA appears to increase vasodilation, with parallel increases in NO production. However, it remains to be determined whether these effects are mediated by increases in eNOS.
In summary, we have found that in vivo estrogen treatment increases eNOS protein and NOS activity in cerebral blood vessels. In vitro treatment of intact cerebral vessels with estrogen also causes a concentration-dependent increase in eNOS protein that is completely inhibited by estrogen receptor blockade. These data are consistent with the hypothesis that estrogen acts on estrogen receptors in cerebrovascular tissue, resulting in increased eNOS protein and NOS activity. Furthermore, using a rodent model for 3 different modalities of postmenopausal hormone therapy, we found that estrogeninduced increases in eNOS are preserved when estrogen is combined with either progesterone or MPA. It is not known, however, whether other possible neuroprotective actions of estrogen are influenced by MPA. This question can now be addressed with the use of the rat model developed in the present study.
